ALCLS Cellectis S.A.

EPA · FR · Healthcare · Biotechnology · cellectis.com

1.249EUR-0.40%Mkt Cap: 136.74M $P/E: —Today

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and g…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

Genmab A/S - American Depositary Shares

$21.69BUSDP/E 27.4

JAZZ

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap136.74M USD

Enterprise Value5.25M USD

Revenue (TTM)69.37M USD

Gross Profit68.64M USD

Net Income (TTM)-73.47M USD

Revenue/Share0.64 EUR

Last Price1.249 EUR

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees224

CountryFR

SectorHealthcare

IndustryBiotechnology

ISINFR0010425595

Valuation

P/E (Trailing)—

P/E (Forward)-0.79

PEG—

EV/EBITDA-0.10

EV/Revenue0.08

P/S1.98

P/B2.50

EPS (TTM)-0.55

EPS (Forward)-1.58

52W Range

1.0934% of range4.840

52W High4.840 EUR

52W Low1.093 EUR

Profitability

Gross Margin86.57%

Oper. Margin-340.69%

EBITDA Margin-73.13%

Profit Margin-92.66%

ROE-89.05%

ROA-20.82%

Growth

Revenue Growth-62.10%

Earnings Growth—

Cash Flow & Leverage

Operating CF-42.83M USD

CapEx (TTM)3.84M USD

FCF Margin168.75%

FCF Yield85.61%

Net Debt-93.84M USD

Net Debt/EBITDA1.85

Balance Sheet

Debt/Equity1.20

Current Ratio1.37

Quick Ratio1.34

Book Value/Sh0.50 EUR

Cash/Share2.29 EUR

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 EUR

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating—

Target (Mean)6.500 EUR

Upside (mean)+420.4%

Target Range6.500 EUR – 6.500 EUR

# Analysts1

Ownership

Shares Out.72.72M

Float48.58M

Insiders48.01%

Institutions10.86%

Technical

SMA 502.286 (-45.4%)

SMA 2002.946 (-57.6%)

Beta2.77

S&P 52W Chg14.58%

Avg Vol (30d)506.51K

Avg Vol (10d)403.46K

Technical Indicators

RSI (14)29.0

MACD-0.3501

MACD Signal-0.3561

MACD Hist.+0.0060

BB Upper2.984 EUR

BB Middle1.661 EUR

BB Lower0.3386 EUR

BB Width159.24%

ATR (14)0.1530 EUR

Vol Ratio (20d)0.40x